Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

[Do thiazolidinediones harm skeletal integrity?].

Takeuchi Y.

Clin Calcium. 2008 May;18(5):650-5. doi: CliCa0805650655. Review. Japanese.

PMID:
18445884
2.

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.

Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE.

Transl Res. 2013 Mar;161(3):145-55. doi: 10.1016/j.trsl.2012.08.006. Epub 2012 Sep 27.

3.

Skeletal consequences of thiazolidinedione therapy.

Grey A.

Osteoporos Int. 2008 Feb;19(2):129-37. Epub 2007 Sep 28. Review.

PMID:
17901911
4.

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

Lecka-Czernik B.

Curr Osteoporos Rep. 2010 Dec;8(4):178-84. doi: 10.1007/s11914-010-0027-y. Review.

5.

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC.

J Endocrinol. 2004 Oct;183(1):203-16.

6.

Thiazolidinedione-induced skeletal fragility--mechanisms and implications.

Grey A.

Diabetes Obes Metab. 2009 Apr;11(4):275-84. doi: 10.1111/j.1463-1326.2008.00931.x. Epub 2008 Jul 29. Review.

PMID:
18671797
7.

[Thiazolidinediones and skeletal health].

Meier C, Bodmer M, Meier CR, Kraenzlin ME.

Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Review. French.

PMID:
19626930
8.

Bone as a target of type 2 diabetes treatment.

Lecka-Czernik B.

Curr Opin Investig Drugs. 2009 Oct;10(10):1085-90. Review.

PMID:
19777397
9.

[Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].

Okazaki R.

Clin Calcium. 2008 Aug;18(8):1154-61. doi: CliCa080811541161. Review. Japanese.

PMID:
18677054
10.

Impact of diabetes and its treatments on skeletal diseases.

Yan W, Li X.

Front Med. 2013 Mar;7(1):81-90. doi: 10.1007/s11684-013-0243-9. Epub 2013 Feb 2. Review.

PMID:
23377889
11.

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Soccio RE, Chen ER, Lazar MA.

Cell Metab. 2014 Oct 7;20(4):573-91. doi: 10.1016/j.cmet.2014.08.005. Epub 2014 Sep 18. Review.

12.

Diabetes and skeletal health.

Yaturu S.

J Diabetes. 2009 Dec;1(4):246-54. doi: 10.1111/j.1753-0407.2009.00049.x. Epub 2009 Aug 17. Review.

13.

Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE.

Br J Pharmacol. 2008 Feb;153(4):636-45. Epub 2007 Oct 1. Review.

14.

Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.

Schwartz AV, Sellmeyer DE.

Expert Opin Drug Saf. 2008 Jan;7(1):69-78. doi: 10.1517/14740338.7.1.69 . Review.

PMID:
18171315
15.

The safety of thiazolidinediones.

Tolman KG.

Expert Opin Drug Saf. 2011 May;10(3):419-28. doi: 10.1517/14740338.2011.534982. Epub 2011 Mar 3. Review.

PMID:
21366501
16.

[Overview: derangement of bone metabolism in diabetes mellitus].

Takeuchi Y.

Clin Calcium. 2009 Sep;19(9):1247-55. doi: CliCa090912471255. Review. Japanese.

PMID:
19721195
17.

Antidiabetic therapy effects on bone metabolism and fracture risk.

Montagnani A, Gonnelli S.

Diabetes Obes Metab. 2013 Sep;15(9):784-91. doi: 10.1111/dom.12077. Epub 2013 Feb 24. Review.

PMID:
23368527
18.

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE; ADOPT Study Group..

J Clin Endocrinol Metab. 2010 Jan;95(1):134-42. doi: 10.1210/jc.2009-0572. Epub 2009 Oct 29.

PMID:
19875477
19.

A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.

Seufert J, Lübben G, Dietrich K, Bates PC.

Clin Ther. 2004 Jun;26(6):805-18. Review.

PMID:
15262452
20.

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.

Berberoglu Z, Yazici AC, Demirag NG.

Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12. doi: 10.1111/j.1365-2265.2010.03784.x. Epub 2010 Feb 10.

PMID:
20148906

Supplemental Content

Support Center